Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Summary of publications:
Publications (original articles or review articles) published in 2018 from OUS - Section for Lymphoma and Medicine
14 publications found
Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL
Blood Cells Mol Dis, 73, 25-32
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
Lancet Haematol, 5 (8), e359-e367
18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?
J Nucl Med, 59 (10), 1524-1530
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
Br J Haematol, 183 (2), 225-234
Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma
Brain Behav, 8 (3), e00928
The role of surgery in intracranial PCNSL
Neurosurg Rev, 41 (4), 1037-1044
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up
J Clin Oncol, 36 (33), 3315-+
Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?
Neuroradiology, 60 (7), 703-713
Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens
Blood, 132 (22), 2401-2405
Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
Br J Haematol, 184 (4), 616-624
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
N Engl J Med, 380 (1), 45-56
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
Eur J Nucl Med Mol Imaging, 45 (7), 1233-1241
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Blood, 132 (20), 2115-2124
Sample-Index Misassignment Impacts Tumour Exome Sequencing
Sci Rep, 8 (1), 5307